Boehringer Ingelheim Pharma GmbH and Co. KG
Boehringer Ingelheim Pharma GmbH and Co. KG is a drug establishment in Biberach an der Riss, Germany, registered with the US FDA under FEI 3002806518. Its registered operations are: Analytical testing, API manufacture, Labelling, Drug manufacture, Packaging. 18 EU/UK GMP certificates are matched to this site, 14 inspected within the last three years.
Sources: FDA Drug Establishments Current Registration Site (checked 2 Nov 2026); EudraGMDP; MHRA GMDP. Methodology
Registered operations
Business operations this establishment declares in its FDA registration. Registration is not an approval and says nothing about EU or UK GMP status.
GMP documents matched to this site (18)
| Document | Authority | Inspection | Source |
|---|---|---|---|
DE_BW_01_GMP_2026_0176 GMP certificate | Competent authority of Germany | 16 Jul 2026 within 3-year review window | EudraGMDP |
DE_BW_01_GMP_2026_0177 GMP certificate | Competent authority of Germany | 16 Jul 2026 within 3-year review window | EudraGMDP |
DE_BW_01_GMP_2026_0130 GMP certificate | Competent authority of Germany | 26 Mar 2026 within 3-year review window | EudraGMDP |
DE_BW_01_GMP_2026_0133 GMP certificate | Competent authority of Germany | 26 Mar 2026 within 3-year review window | EudraGMDP |
DE_BW_01_GMP_2026_0129 GMP certificate | Competent authority of Germany | 26 Mar 2026 within 3-year review window | EudraGMDP |
DE_BW_01_GMP_2026_0134 GMP certificate | Competent authority of Germany | 26 Mar 2026 within 3-year review window | EudraGMDP |
DE_BW_01_GMP_2025_0061 GMP certificate | Competent authority of Germany | 13 Feb 2025 within 3-year review window | EudraGMDP |
DE_BW_01_GMP_2025_0063 GMP certificate | Competent authority of Germany | 13 Feb 2025 within 3-year review window | EudraGMDP |
DE_BW_01_GMP_2024_0179 GMP certificate | Competent authority of Germany | 5 Sept 2024 within 3-year review window | EudraGMDP |
DE_BW_01_GMP_2024_0178 GMP certificate | Competent authority of Germany | 5 Sept 2024 within 3-year review window | EudraGMDP |
DE_BW_01_GMP_2024_0170 GMP certificate | Competent authority of Germany | 13 Jun 2024 within 3-year review window | EudraGMDP |
DE_BW_01_GMP_2024_0169 GMP certificate | Competent authority of Germany | 13 Jun 2024 within 3-year review window | EudraGMDP |
DE_BW_01_GMP_2024_0161 GMP certificate | Competent authority of Germany | 15 May 2024 within 3-year review window | EudraGMDP |
DE_BW_01_GMP_2024_0162 GMP certificate | Competent authority of Germany | 15 May 2024 within 3-year review window | EudraGMDP |
DE_BW_01_GMP_2023_0193 GMP certificate | Competent authority of Germany | 11 Oct 2023 outside 3-year review window | EudraGMDP |
DE_BW_01_GMP_2023_0192 GMP certificate | Competent authority of Germany | 11 Oct 2023 outside 3-year review window | EudraGMDP |
DE_BW_01_GMP_2023_0154 GMP certificate | Competent authority of Germany | 27 Jul 2023 outside 3-year review window | EudraGMDP |
DE_BW_01_GMP_2023_0155 GMP certificate | Competent authority of Germany | 27 Jul 2023 outside 3-year review window | EudraGMDP |
A GMP document is matched to this site when its address names the site's street and its city or postcode. In our latest internal review 59 of 60 sampled matches were the right site (not yet independently reviewed; measured match quality). Check the certificate's own address before relying on it. The three-year review window is the EMA guideline default after an inspection, not an official expiry date.
What this page does not show
- Which substances are made here: DMFs and CEPs are filed by organisations, not sites, so we do not link substances to this site.
- Capacity, scale, price or current availability: no regulator publishes these.
- FDA inspection classifications for this site, which are not yet linked.